ASCO 2024 | BELLWAVE-011: nemtabrutinib vs ibrutinib/acalabrutinib in treatment-naïve CLL/SLL
Tamar Tadmor
• 31 May 2024
Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, introduces BELLWAVE-011 (NCT06136559), a global Phase III trial comparing nemtabrutinib, an irreversible non-covalent BTK inhibitor (BTKi), to investigator’s choice of ibrutinib or acalabrutinib in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
